KCT0004597Active, not recruiting未知
A prospective study on efficacy and safety of insulin degludec/insulin aspart compared to insulin glargine and the relation with glycemic variability in patients with type 2 diabetes
Trial Snapshot
- Phase
- 未知
- Status
- Active, not recruiting
- Enrollment
- 55
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 18(Year) to o Limit (—)
- Sex
- All
Inclusion Criteria
- •1. patients in the outpatient clinic of SNUH, with type 2 diabetes
- •2. age > 19 years
- •3. under treatment with once-daily basal insulin (< 1 IU/kg) for more than 4 months
- •4. HbA1c >= 7% and <=10%
- •5. marked postprandial hyperglycemia estimated by FPG and HbA1c
- •6. No change in blood sugar lowering medication taken during the study period
Exclusion Criteria
- •1. Type 1 diabetes
- •2. When using insulin other than Insulin glargine U100, Insulin glargine U300, and insulin degludec
- •3. pregnancy, breast feeding
- •4. major CVD events or malignancy with the past 6 months
- •5. uncontrolled hypertension
- •6. any medications or serious diseases known to significantly affect weight or glucose metabolism
- •7. irregular diet
Investigators
Similar Trials
Completed
Phase 2
Prospective analysis of efficacy and safety of individualized administration of midazolam for sedation during bronchoscopyJPRN-UMIN000003971agoya University Graduate School of Medicine200
Not yet recruiting
Not Applicable
A prospective study about efficacy and safety of selective arterial injection chemotherapy for ineffective or intorelable to the standard chemotherapy in advanced esophageal cancerEsophagusJPRN-UMIN000028542Showa University Koto Toyosu Hospital50
Recruiting
Not Applicable
Prospective Study of the Efficacy, Safety and Identification of Predictors of Gefapixant for Refractory Chronic CoughRefractory Chronic CoughJPRN-UMIN000047917Japanese Red Cross Medical Center50
Active, not recruiting
Phase 1
Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstructioInoperable malignant bowel obstructionMedDRA version: 9.1Level: LLTClassification code 10006055Term: Bowel obstructionEUCTR2009-012981-30-BEniversity Hospital Ghent40
Recruiting
Phase 3
Effect of insulin glucose solution in orthotopic liver transplantatioIRCT20240606062025N1Shahid Beheshti University of Medical Sciences70